ada standards of care 2025 glp-1 dpp-4 combination not recommended The American Diabetes Association Releases in Diabetes-- The Latest topics of Standards

By understanding their individual benefits and potential synergies, individuals can make informed choices that align with their health goals

("Sciwind"), a biopharmaceutical company focused on the discovery and development of innovative therapies for metabolic diseases, announced that China's National Medical Products Administration (NMPA) has approved ecnoglutide injection for glycemic control in adults with type 2 diabetes mellitus (T2DM), making it the world's first approved cAMP-biased GLP-1 receptor agonist

Lactobacillus rhamnosus LC-STH-13 alleviates renal inflammation and complement-mediated kidney injury by inhibiting the TLR9/NF-B pathway while suppressing SLE progression through gut microbiota restoration, offering a novel therapeutic strategy [81]

demonstrated that carnitine supplementation significantly increased heart rate variability (HRV) in patients suffering from severe cardiac dysautonomia